All In Biotech

Drug Trial Radar · NCT05270837

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) With Phenylketonuria- Open-Label Randomized Two-Arm (Active vs Diet-Only Control)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

55

Actual

Start

Jun 17, 2022

Primary completion

Jan 14, 2025

Study completion Oct 2027

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.

Conditions

  • Phenylketonuria (PKU)

Interventions

  • PegvaliaseDrug

    Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week

  • Diet OnlyOther

    Diet Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.Time frame: Baseline to Week 72 (average of the Week 69 and Week 73)
  2. Incidence of Treatment-emergent Adverse Events (Part 1)Time frame: Up to Week 73
  3. Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)Time frame: Baseline (Day 1), Week 73
  4. Percentage of Participants With Positive PAL IgG AntibodyTime frame: Baseline (Day 1), Week 73
  5. Percentage of Participants With Positive PAL IgM AntibodyTime frame: Baseline (Day 1), Week 73
  6. Percentage of Participants With Positive PEG IgG AntibodyTime frame: Baseline (Day 1), Week 73
  7. Percentage of Participants With Positive PEG IgM AntibodyTime frame: Baseline (Day 1), Week 73
  8. Percentage of Participants With Positive Neutralizing Antibodies (NAb)Time frame: Baseline (Day 1), Week 73

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Children's Hospital of Colorado

    Aurora, Colorado

  • University of South Florida

    Tampa, Florida

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • IU Health University Hospital

    Indianapolis, Indiana

  • University of Kentucky College of Medicine

    Lexington, Kentucky

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth)

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

  • University of Virginia School of Medicine

    Charlottesville, Virginia

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitat Mainz

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.